WinstonWınston
Abivax S.A. logo

Abivax S.A.

ABVX
42
Biotechnology · Healthcare
Price
$136.65
-1.12 (-0.81%)
Market Cap
$10.03B
Exchange
NASDAQ
Winston Score
42
Winston is serious
Mixed quality — meaningful strengths and weaknesses.

Share count rising — dilution

+349.8% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 15.5M (2021) → 69.5M (2025)

ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX

Winston Score History

Politician Trades

2 trades / 12mo

1 Congressional buy and 1 sell on ABVX in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-127.3% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-104.0% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$178M/ year

Rising (+21% vs prior year)

R&D investment increasing — building for the future

Insider Activity

10.2%ownership

Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~22 months

$516M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Adequate runway but may need to raise capital within 2 years

Revenue declining

Abivax S.A.'s revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
151.1%
Premium pricing power — 151.1% gross margin
Operating Margin
7289.9%
Excellent — 7289.9% operating margin
ROCE
-30.2%
Weak — -30.2% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
+19.2%
Fast-growing sales (19.2% YoY)
EPS YoY
N/A
Data not available
EPS Consistency
0/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
N/A
Data not available
FCF Margin
-2314.5%
Burning cash (-2314.5%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
0.07
Conservative — low debt load (0.07)
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
N/M
Negative earnings — P/E not meaningful
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial